Recent studies have explored various treatment modalities for meningiomas, particularly focusing on surgical approaches and radiosensitization strategies. One significant study evaluated the use of NAD+ metabolic enzyme inhibitors, specifically FK866, in combination with radiation therapy for malignant meningiomas. The findings demonstrated that this combination treatment significantly increased the number of G2/M-phase cells and apoptotic cells, indicating enhanced radiosensitivity and antitumor efficacy compared to either treatment alone (ref: Lv doi.org/10.1158/1535-7163.MCT-23-0632/). Another important aspect of treatment is the timing of surgical resection for spinal meningiomas, where early-stage resection was shown to positively influence neurological outcomes and quality of life, although the optimal timing remains debated (ref: Schwake doi.org/10.3390/cancers16132336/). Furthermore, the impact of fractionation regimens in stereotactic radiosurgery (SRS) was assessed, revealing no significant differences in local control rates among various treatment schedules, with local control rates at 5 years reaching 97.4% (ref: Beighley doi.org/10.1016/j.wneu.2024.07.148/). These findings underscore the complexity of treatment decisions in meningioma management, highlighting the need for personalized approaches based on tumor characteristics and patient factors. In addition to surgical and radiotherapy strategies, the expression of somatostatin receptors in canine and feline meningiomas was investigated, revealing that SSTR1 and SSTR2 were consistently expressed in canine samples, which may have implications for targeted therapies in veterinary medicine (ref: Immler doi.org/10.1002/vms3.1537/). The exploration of novel therapeutic combinations, such as the synergistic effects of PAK and Hippo pathway inhibitors in NF2-deficient schwannomas, also indicates a broader interest in understanding the molecular underpinnings of meningioma biology to inform treatment strategies (ref: Benton doi.org/10.1371/journal.pone.0305121/). Overall, the integration of molecular insights and advanced surgical techniques is paving the way for improved outcomes in meningioma treatment.

The biological and molecular characteristics of meningiomas have been the focus of several recent studies, particularly regarding genetic predispositions and diagnostic advancements. A groundbreaking genome-wide association study (GWAS) conducted on Japanese patients identified specific single nucleotide polymorphisms (SNPs) associated with meningioma susceptibility, marking a significant step in understanding the genetic etiology of these tumors in East Asian populations (ref: Yamada doi.org/10.1007/s11060-024-04727-x/). This study not only contributes to the global understanding of meningioma risk factors but also sets the stage for future research aimed at identifying genetic markers that could guide screening and prevention strategies. In parallel, advancements in diagnostic techniques have emerged, particularly the use of infrared (IR) spectroscopy to predict the WHO grade and methylation class of aggressive meningiomas. This innovative approach demonstrated the capability to differentiate between malignant and benign tumor types based on molecular characteristics, potentially allowing for real-time intraoperative assessments (ref: Galli doi.org/10.1093/noajnl/). The integration of these molecular insights with clinical data is crucial for developing tailored treatment plans and improving prognostic accuracy. Moreover, the analysis of treatment planning metrics in stereotactic radiosurgery highlighted the importance of tumor morphology in predicting treatment outcomes, emphasizing the need for personalized approaches based on individual tumor characteristics (ref: Singh doi.org/10.4103/jcrt.jcrt_36_24/). Collectively, these studies underscore the dynamic interplay between molecular biology and clinical practice in the management of meningiomas.

Innovations in imaging techniques have significantly enhanced the diagnostic capabilities for meningiomas, with a focus on improving classification accuracy and treatment planning. A novel deep learning model, Res-BRNet, was developed for brain tumor MRI classification, demonstrating promising results in accurately distinguishing between various tumor types, including meningiomas. This advancement suggests that deep learning can substantially improve clinical diagnosis and treatment planning efficiency (ref: Zahoor doi.org/10.3390/biomedicines12071395/). The integration of artificial intelligence in imaging not only streamlines the diagnostic process but also aids in the identification of tumor characteristics that may influence treatment strategies. Additionally, the impact of social determinants on the receipt of adjuvant radiation therapy following atypical meningioma surgery was examined, revealing disparities based on geographic location and insurance status. Patients living further from treatment facilities or those without insurance were less likely to receive necessary radiation therapy, highlighting the need for targeted interventions to address these inequities (ref: Chisango doi.org/10.1016/j.wneu.2024.07.140/). Furthermore, a study on stress levels among patients diagnosed with meningioma indicated that these individuals experience higher perceived stress compared to those without the diagnosis, which may influence treatment adherence and overall quality of life (ref: Menlibayeva doi.org/10.1002/cnr2.2105/). These findings emphasize the importance of considering both technological advancements and social factors in the comprehensive management of meningiomas.

Epidemiological studies have shed light on the risk factors associated with meningiomas, with a particular focus on genetic predispositions and environmental influences. The aforementioned GWAS conducted in Japan has provided critical insights into the genetic factors contributing to meningioma susceptibility, identifying specific SNPs that may serve as biomarkers for risk assessment in East Asian populations (ref: Yamada doi.org/10.1007/s11060-024-04727-x/). This research is pivotal in expanding the understanding of the epidemiology of meningiomas and may guide future studies aimed at identifying additional risk factors. Moreover, the role of radiosensitization in malignant meningiomas was explored through the investigation of NAMPT inhibition, which demonstrated enhanced radiosensitivity and increased apoptosis in tumor cells when combined with radiation therapy (ref: Lv doi.org/10.1158/1535-7163.MCT-23-0632/). This finding not only underscores the potential for targeted therapies to improve treatment outcomes but also highlights the importance of understanding the biological mechanisms underlying tumor response to therapy. The interplay between genetic predispositions and treatment responses is crucial for developing personalized treatment strategies that consider both the biological characteristics of the tumor and the individual patient's risk profile.

Research on patient outcomes and quality of life (QoL) following meningioma treatment has gained traction, emphasizing the importance of timing and treatment modalities. A study investigating the timing of resection for spinal meningiomas found that early-stage surgery significantly improved neurological outcomes and QoL, particularly in patients with mild symptoms (ref: Schwake doi.org/10.3390/cancers16132336/). This highlights the critical role of timely intervention in optimizing patient outcomes and underscores the need for careful consideration of surgical timing in clinical practice. In addition, the potential of multi-parameter MRI radiomic features to predict progression-free survival in patients with WHO grade II meningiomas was explored, revealing that these imaging biomarkers could provide valuable prognostic information (ref: Zeng doi.org/10.3389/fonc.2024.1246730/). Such advancements in imaging not only enhance prognostic capabilities but also contribute to personalized treatment planning. Furthermore, a comprehensive survey of treatment practices for elderly patients with meningiomas revealed significant variations in management approaches, indicating the necessity for standardized guidelines to improve care for this demographic (ref: Ius doi.org/10.1007/s10143-024-02524-8/). Collectively, these studies emphasize the importance of integrating patient-centered approaches and advanced diagnostic tools to enhance outcomes and QoL for individuals affected by meningiomas.

Technological advancements in neurosurgery have significantly transformed the management of meningiomas, particularly through innovative surgical techniques and improved imaging modalities. The lateral transorbital neuroendoscopic approach has emerged as a preferred method for accessing tumors in the orbital apex and spheno-orbital region, demonstrating high efficacy and safety in a series of consecutive cases (ref: Zoia doi.org/10.1016/j.bas.2024.102856/). This technique allows for minimally invasive access to challenging tumor locations, potentially reducing recovery times and improving patient outcomes. Moreover, a systematic review and meta-analysis of stereotactic radiosurgery for intraventricular meningiomas revealed a tumor control proportion of 92% for primary cases, underscoring the effectiveness of this treatment modality for rare tumor subtypes (ref: Khaboushan doi.org/10.1007/s00701-024-06185-w/). The integration of advanced imaging techniques, such as MRI and CT, with stereotactic approaches enhances the precision of tumor targeting and treatment delivery. Additionally, the analysis of treatment planning metrics in Gamma Knife stereotactic radiosurgery highlighted the significance of tumor morphology in predicting treatment outcomes, reinforcing the need for tailored approaches based on individual patient characteristics (ref: Singh doi.org/10.4103/jcrt.jcrt_36_24/). These technological innovations are pivotal in advancing the field of neurosurgery and improving the management of meningiomas.

Radiotherapy remains a cornerstone in the management of meningiomas, with ongoing research focused on optimizing treatment efficacy through radiosensitization strategies. A pivotal study investigated the role of NAD+ metabolic enzyme inhibition in enhancing radiosensitivity in malignant meningiomas, demonstrating that the combination of FK866 with radiation therapy significantly increased apoptotic cell populations and G2/M-phase cell accumulation (ref: Lv doi.org/10.1158/1535-7163.MCT-23-0632/). This finding suggests that targeting metabolic pathways may enhance the effectiveness of conventional radiotherapy, providing a promising avenue for improving treatment outcomes in aggressive tumor types. In addition, the impact of fractionation regimens in stereotactic radiosurgery was evaluated, revealing no significant differences in local control rates across various treatment schedules, with local control rates at 5 years reaching 97.4% (ref: Beighley doi.org/10.1016/j.wneu.2024.07.148/). This consistency in outcomes across different fractionation approaches emphasizes the robustness of stereotactic techniques in managing meningiomas. Furthermore, the influence of social determinants on the receipt of adjuvant radiation therapy was highlighted, indicating disparities in treatment access based on geographic and socioeconomic factors (ref: Chisango doi.org/10.1016/j.wneu.2024.07.140/). These insights underscore the importance of addressing both biological and social factors in the development of effective radiotherapy strategies for meningioma patients.

Research on veterinary meningiomas has provided valuable insights into the similarities and differences between human and canine/feline tumors, particularly regarding treatment responses and receptor expression. A study investigating the cytotoxic effects of somatostatin analogs, specifically octreotide, on low-grade canine meningiomas demonstrated significant cell death at higher concentrations, suggesting potential therapeutic applications in veterinary oncology (ref: Mandara doi.org/10.1093/noajnl/). This research not only contributes to the understanding of meningioma biology in dogs but also raises the possibility of translating findings to human medicine. Additionally, the expression of somatostatin receptors in canine and feline meningiomas was evaluated, revealing that SSTR1 and SSTR2 were consistently expressed in canine samples, while SSTR3 was less frequently detected (ref: Immler doi.org/10.1002/vms3.1537/). These findings may inform the development of targeted therapies in veterinary practice and highlight the potential for comparative studies to enhance the understanding of meningioma biology across species. The exploration of treatment modalities and receptor expression in veterinary meningiomas underscores the importance of interdisciplinary research in advancing therapeutic strategies for both human and animal patients.